Amphastar Pharmaceuticals (AMPH) PT Raised to $23 at Jefferies
Tweet
Share
E-mail
Get Alerts AMPH Hot Sheet
Price: $19.64 -2.29%
Rating Summary:
2 Buy, 8 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 4 | Down: 6 | New: 18
Rating Summary:
2 Buy, 8 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 4 | Down: 6 | New: 18
Join SI Premium – FREE
Jefferies raised its price target on Amphastar Pharmaceuticals (NASDAQ: AMPH) to $23.00 (from $19.00) while maintaining a Buy rating.
Analyst David Steinberg notes revenue for the quarter came in slightly above their estimates at $57.9M largely due to better than expected Naloxone revs. The EPS beat was partially due to lower R&D spend.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Truist Securities Downgrades Procept BioRobotics Corp (PRCT) to Hold
- BofA Securities Downgrades Amphastar Pharmaceuticals (AMPH) to Underperform
- Baker Hughes (BKR) PT Raised to $77 at TD Cowen
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, Analyst PT ChangeRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
